SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-007096
Filing Date
2024-02-20
Accepted
2024-02-20 06:19:50
Documents
47
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 535163
2 ex10-11.htm EX-10.11 297946
3 ex10-12.htm EX-10.12 162748
4 ex31-1.htm EX-31.1 18676
5 ex31-2.htm EX-31.2 18650
6 ex32-1.htm EX-32.1 6919
7 ex32-2.htm EX-32.2 6916
  Complete submission text file 0001493152-24-007096.txt   3447017

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE nxen-20231231.xsd EX-101.SCH 20380
9 XBRL CALCULATION FILE nxen-20231231_cal.xml EX-101.CAL 25516
10 XBRL DEFINITION FILE nxen-20231231_def.xml EX-101.DEF 103621
11 XBRL LABEL FILE nxen-20231231_lab.xml EX-101.LAB 204158
12 XBRL PRESENTATION FILE nxen-20231231_pre.xml EX-101.PRE 165847
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 334611
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

IRS No.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 24650588
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)